<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956448</url>
  </required_header>
  <id_info>
    <org_study_id>M-20110037</org_study_id>
    <nct_id>NCT01956448</nct_id>
  </id_info>
  <brief_title>SORT-OUT VI - Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity®</brief_title>
  <acronym>SO VI</acronym>
  <official_title>Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity® Coronary Stents in Non-selected Patients With Ischemic Heart Disease The SORT OUT VI Study*</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosensors International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To perform a randomized comparison between the BioMatrix Flex™ and the Resolute Integrity®
      stents in the treatment of unselected patients with ischemic heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SORT OUT VI is a randomized, multicenter, all-comer, two-arm, non-inferiority trial comparing
      the Biolimus-eluting Biomatrix Flex and the Zotarolimus-eluting Medtronic Resolute Integrity
      in treatment of atherosclerotic coronary artery lesions.

      Primary Endpoint:

      Target lesion failure within 12 months of stent implantation (combination of cardiac death,
      myocardial infarction (not index procedure related) not related to other than index lesion or
      target lesion revascularization).

      Secondary Endpoints:

      Individual components of the primary end point comprised the secondary end points and stent
      thrombosis rate according to the Academic Research Consortium definition (see protocol for
      further specification of secondary endpoints).

      Clinically driven event detection will be used to avoid study-induced reinterventions. Data
      on mortality, hospital admission, coronary angiography, repeat percutaneous coronary
      intervention, and coronary bypass surgery will be obtained for all randomly allocated
      patients from the following national Danish administrative and healthcare registries: the
      Civil Registration System; the Western Denmark Heart Registry; the Danish National Registry
      of Patients, which maintains records on all hospitalizations in Denmark; and the Danish
      Registry of Causes of Death
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-related combined endpoint</measure>
    <time_frame>1,2,3 and 5 years</time_frame>
    <description>Device-related combined endpoint hierarchically:
cardiac death, non-index procedure related acute myocardial infarction not clearly related to another lesion than the target lesion (new revascularization by PCI or CABG) within 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of contrast</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint of cardiac death, non-index procedure related acute myocardial infarction, not clearly related to another lesion than target lesion, target lesion revascularisation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularisation</measure>
    <time_frame>1,2,3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and myocardial infarction</measure>
    <time_frame>1 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1,2,3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related combined endpoint hierarchically cardiac death, non-index procedure related AMI, not clearly related to another lesion than target lesion</measure>
    <time_frame>2,3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-related combined endpoint hierarchically: all-cause death, non-index procedure related acute myocardial infarction, all new revascularizations</measure>
    <time_frame>1,2,3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2800</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Drug eluting stent (BioMatrix Flex)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug eluting stent (Resolute Integrity)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting stent</intervention_name>
    <description>Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)</description>
    <arm_group_label>Drug eluting stent (BioMatrix Flex)</arm_group_label>
    <arm_group_label>Drug eluting stent (Resolute Integrity)</arm_group_label>
    <other_name>BioMatrix Flex - biolimus eluting stent</other_name>
    <other_name>Resolute - zotarolimus eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or over with chronic stable coronary artery disease or acute
             coronary syndromes, and at least one coronary artery lesion with more than 50%
             diameter stenosis, requiring treatment with a drug-eluting stent.

        Exclusion Criteria:

          -  life expectancy of less than one year

          -  an allergy to aspirin, clopidogrel, ticagrelor, prasugrel, sirolimus, or biolimus

          -  participation in another randomized trial

          -  inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Ravkilde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Universitetshospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Skejby</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>October 6, 2013</last_update_submitted>
  <last_update_submitted_qc>October 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Evald Hoej Christiansen</investigator_full_name>
    <investigator_title>MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>DES</keyword>
  <keyword>Angina pectoris</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

